Beam Therapeutics (BEAM) Equity Average (2019 - 2025)
Historic Equity Average for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $1.0 billion.
- Beam Therapeutics' Equity Average rose 2232.9% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 2232.9%. This contributed to the annual value of $857.4 million for FY2024, which is 0.41% changed from last year.
- Beam Therapeutics' Equity Average amounted to $1.0 billion in Q3 2025, which was up 2232.9% from $1.1 billion recorded in Q2 2025.
- In the past 5 years, Beam Therapeutics' Equity Average registered a high of $1.1 billion during Q2 2025, and its lowest value of $334.0 million during Q1 2021.
- In the last 5 years, Beam Therapeutics' Equity Average had a median value of $814.6 million in 2022 and averaged $796.3 million.
- Per our database at Business Quant, Beam Therapeutics' Equity Average surged by 100796.15% in 2021 and then plummeted by 1384.07% in 2022.
- Over the past 5 years, Beam Therapeutics' Equity Average (Quarter) stood at $840.3 million in 2021, then dropped by 13.84% to $724.0 million in 2022, then rose by 21.57% to $880.1 million in 2023, then decreased by 13.37% to $762.4 million in 2024, then soared by 32.0% to $1.0 billion in 2025.
- Its Equity Average stands at $1.0 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $928.3 million for Q1 2025.